Fukushima Ryan sold $6K of TEM (indirect holdings)

Fukushima Ryan (CEO, Data) sold 80 indirectly-held shares of Tempus AI, Inc. (TEM) at $74.29 on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fukushima Ryan
Published Nov 4, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
high confidence
Mentioned
$TEM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

The disclosed sale is small and pre‑arranged, suggesting limited immediate market impact.

02

Market read

Primary insider sale filing with modest size; low trading relevance.

03

What to watch

Insider ownership remains sizable (15,794 shares) and the sale was pre‑arranged under a 10b5‑1 plan.

Relevance 2/10Novelty 2/10Timing: after-hours filing

Background

Form 4 filings disclose insider transactions; traders watch for material sales that could signal confidence changes.

Company-level read

Ticker impact

$TEMBearishHigh confidence
Context

CEO Fukushima Ryan sold 80 shares of Tempus AI for $5,943, indicating a small insider divestment.

Expected impact

likely pressure as the market prices in the insider sell.

Evidence & confidence

Form 4 filing is a primary source; the transaction size is small relative to float, but any insider sell can be viewed negatively by traders.

Market effects

Minimal impact on the AI/health‑tech sector; the sale is company‑specific.

No broader regional effect.

Limited to Tempus AI investors.

Counterpoint

The sale may be routine portfolio rebalancing and not a signal of weakness.

Key entities

  • Tempus AI, Inc.

    AI‑driven healthcare data company (ticker TEM).

  • Fukushima Ryan

    CEO of Tempus AI, reporting a sale of personal holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.